Acessa Health | August 12, 2020
Acessa Health reaches 4,000 cases, marking growing excitement for Laparoscopic Radiofrequency Ablation (Lap-RFA.)
See the full press release on the Business Wire.
AUSTIN, Texas – 08/06/2020 – Acessa Health Inc., a women’s health innovator advancing uterine-sparing solutions for symptomatic fibroids, announces over 4,000 women treated with laparoscopic radiofrequency ablation (Lap-RFA), the Acessa procedure.1
“Four thousand women treated is more than a milestone. It represents 4,000 lives changed. Whether she is the first, second, 4,000th, or 10,000th woman to get Acessa, we are continually humbled by the opportunity impact her life,” said Kim Rodriguez, CEO.
The 4,000th woman was treated by board certified, gynecologic surgeon, Nicole E. Williams, MD, FACOG, FACS of The Gynecology Institute of Chicago. Williams remarked, “I began offering the procedure years ago because my patients were searching for a minimally invasive option for their fibroids. The results speak for themselves: no suturing of the uterus, quick recovery, long-term symptom relief.”2
“Achieving 4,000 women treated exemplifies how Acessa Health truly elevates the standard of care for fibroid treatment,” said Bruce Lee, MD, who originally conceived the idea of Lap-RFA for fibroids.
Traditionally, the gynecologic community considers minimally invasive to mean the surgeon’s approach – either vaginally or laparoscopically as compared with open surgery. Acessa Health works closely with clinicians as they elevate the definition of minimally invasive gynecology to consider the overall impact to a woman, rather than limiting the definition to incision size.
“A vaginal hysterectomy is a still hysterectomy. A robotic myomectomy is still a myomectomy. Now, thanks to Acessa Health, the gynecology community has a less invasive, yet comprehensive, option to offer women,” said Devin Garza, MD, FACOG Director of Minimally Invasive Surgery at St. David’s North Austin Medical Center and St. David’s Surgical Hospital.
He continued, “The technology and awareness has evolved at an incredible pace. Acessa Health prioritized the right things and is poised to reach the next four thousand women treated quickly.”
In only three years since forming the company, Acessa Health achieved FDA clearance and successfully launched the Acessa ProVu System, one of the most innovative gynecology products the industry has seen in decades– the first and only fully integrated system with laparoscopic ultrasound, radiofrequency ablation, and guidance mapping. Now, surpassing the 4,000th procedure milestone amid a pandemic, speaks to the strong momentum ahead.
When asked the secret to achieving a shift in standard in care such a short amount of time, Kim Rodriguez, CEO said, “It starts with the Acessa team and the partnership with physicians and their women patients. Reaching 4,000 womentreated and elevating the standard of care requires tenacity, visionary thinking, and impeccable execution. The future is bright.”
About the Acessa procedure
The Acessa procedure is a minimally invasive, outpatient treatment that involves two small abdominal incisions.2 It uses controlled radiofrequency energy, heat, to cause coagulative necrosis of the fibroid tissue. The treated tissue softens and shrinks over time, allowing fibroid symptoms to resolve with no suturing of the uterine tissue.3 Unlike many alternative interventions, the Acessa procedure optimizes imaging of the uterus by simultaneously displaying the laparoscopic camera view and the ultrasound view in real-time, so physicians can identify and treat nearly all locations of fibroids, including those outside the uterine cavity and within uterine walls.3 Women typically experience minimal discomfort after the procedure, quick return to normal activities in 4-5 days, and long term satisfaction and relief.2,3
About Acessa Health Inc.
Acessa Health is a women’s health innovator dedicated to advancing minimally invasive, uterine-sparing solutions for women with symptomatic fibroids. The company introduced the use of radiofrequency ablation under laparoscopic ultrasound guidance for the treatment of uterine fibroids. Acessa is continuing to develop technologies that give women more options. Acessa Health’s headquarters are in Austin, Texas. For more information, visit www.acessaprocedure.com
- Acessa data on file
- Yelena Havryliuk, MD, Robert Setton, MD, John Carlow, EdD, MPH, Barry D. Shaktman, MD, Management of symptomatic fibroids: review and meta-analysis of the literature (2006 -2016), Journal of the Society of Laparoendoscopic Surgeons, Vol. 21 (3) Jul-Sept 2017
- SG Chudnoff, et al. Outpatient Procedure for the Treatment and Relief of Symptomatic Uterine Myomas. Obstetrics and Gynecology, 2013;121(5):1075–82.
There are potential risks associated with the Acessa procedure. It may not be appropriate for all patients and all patients may not benefit. For information about the indications, contraindications, warnings, and precautions, visit: www.acessaprocedure.com. Rx
Contact information: Elaine Horton [email protected]